Healio highlights AI adherence
- Healio reported April 27 that Siamak Yousefi told the American Glaucoma Society meeting artificial intelligence could identify glaucoma patients drifting off eye-drop treatment. - Yousefi said glaucoma’s slow, often symptom-free course makes missed drops hard to spot, and he pitched automated alerts plus chatbots between visits. - Wider glaucoma adoption still hinges on workflow, cost, reimbursement and patient acceptance. (ophthalmologytimes.com)
Glaucoma slowly damages the optic nerve, and many patients use daily eye drops to keep pressure down before vision loss becomes obvious. (healio.com) (pmc.ncbi.nlm.nih.gov) At the American Glaucoma Society annual meeting in Rancho Mirage, California, Siamak Yousefi, PhD, said artificial intelligence could help clinicians spot patients who are becoming nonadherent with those drops. The meeting ran Feb. 19-22, 2026. (healio.com) (americanglaucomasociety.net) Healio quoted Yousefi saying nonadherence is common because glaucoma is often asymptomatic and slow to progress, while treatment can be expensive, complicated, and physically hard to instill. (healio.com) The idea is straightforward: use software to detect patterns that suggest a patient is falling off therapy, then intervene before pressure-related damage shows up on an exam. Healio said Yousefi also pointed to artificial-intelligence chatbots as a way to keep patients engaged between office visits. (healio.com) That pitch fits a broader shift in glaucoma care, where researchers are testing artificial intelligence not just for screening and diagnosis, but also for monitoring and prediction. A March/April 2026 review in *Glaucoma Today* said current work is increasingly aimed at clinically meaningful uses, including detecting progression. (glaucomatoday.com) A 2024 review of artificial intelligence in glaucoma care described the field’s promise across screening, diagnosis, progression forecasting, and treatment support, but also listed limits including dataset quality, bias, privacy, and real-world validation. (pmc.ncbi.nlm.nih.gov) Those same practical limits are hanging over adherence tools. *Ophthalmology Times* reported in January that artificial intelligence, home monitoring, and sustained drug delivery could shape glaucoma practice in 2026, but adoption still depends on workflow integration, cost, and patient acceptance. (ophthalmologytimes.com) The American Academy of Ophthalmology made a similar point in 2024 after an American Glaucoma Society symposium, reporting that panelists saw artificial intelligence as a strong fit for glaucoma while also warning about reimbursement, regulation, and clinician trust. (aao.org) For patients, the immediate target is simple: missed drops in a disease that can stay silent for years. For clinics, the test is whether an alert system can reliably identify who needs outreach before preventable vision loss occurs. (healio.com) (ophthalmologytimes.com)
